Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas
Explore this paper's citation graph
Summary
Methylation of the CpG island and promoter of the RASSF1A gene is common not only in lung and breast tumors but also in renal cell carcinoma and ovarian cancer.
- Type
- article
- Published
- 2001-10-15
- Cited by
- 180
- References
- 46
- Access
- Open access
- OpenAlex
- https://openalex.org/W2082337086
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24143630
Keywords
Loss of heterozygosity, Biology, CpG site, Methylation, Cancer research
References
- Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
- Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes.
- Homozygous deletions of human chromosome 3p in lung tumors.
- Alterations in DNA methylation: a fundamental aspect of neoplasia.
- Cancer-epigenetics comes of age
- Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
- Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
- The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
- Accumulation of genetic alterations and progression of primary breast cancer.
- High sensitivity mapping of methylated cytosines.
- The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas
- The VHL tumour-suppressor gene paradigm.
- Novel mutations of the von Hippel‐Lindau tumor‐suppressor gene and rare DNA hypermethylation in renal‐cell carcinoma cell lines of the clear‐cell type
- Inclusion of new microsatellite repeats in allelic loss analysis excludes retention of heterozygosity in the renal cell carcinoma critical region in 3p21.
- Hypermethylation of the APC (adenomatous Polyposis Coli) gene promoter region in human colorectal carcinoma
- Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype.
- Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma
- Ras Uses the Novel Tumor Suppressor RASSF1 as an Effector to Mediate Apoptosis*
- DNA hypermethylation in tumorigenesis: epigenetics joins genetics.
- Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma.
Cited by
- Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer
- Promoter methylation of GATA4, WIF1, NTRK1 and other selected tumour suppressor genes in ovarian cancer.
- Epigenomics and ovarian carcinoma
- Epigenetic markers of ovarian cancer.
- Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.
- DNA methylation profiles of female steroid hormone-driven human malignancies.
- Genetics, epigenetics and angiogenesis in renal cell carcinoma
- Functional analysis of low-moderate risk susceptibility genes emerging from pathway based approaches and genome wide association studies in epithelial ovarian cancer
- Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes
- On the elucidation of a tumour suppressor role of 3p in lung cancer
- The tumor suppressor RASSF1A in human carcinogenesis: an update.
- Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma
- Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
- Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
- Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study.
- Genetic and epigenetic mechanisms of tumor predisposition in hereditary non-polyposis colorectal carcinoma and sporadic cancers
- Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms
- Association between RASSF1A Promoter Methylation and Ovarian Cancer: A Meta-Analysis
- RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.
- Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines
Related papers
- Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers.
- Loss of heterozygosity at 10q in tumors of the upper respiratory tract is associated with poor prognosis.
- Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.
- Loss of heterozygosity of tumor suppressor genes in testis cancer.
- Loss of Heterozygosity at the 9p21–24 Region and Identification of BRM as a Candidate Tumor Suppressor Gene in Head and Neck Squamous Cell Carcinoma
- Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.
- Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas.
- Determination of loss of heterozygosity using polymerase chain reaction.
- Clinical factors and loss of heterozygosity of APC suppressor gene in oral squamous cell carcinoma
- Loss of heterozygosity of p53 in oral cancers demonstrated by the polymerase chain reaction